AMENDMENT NO. 1 TO ROYALTY Purchase AGREEMENTRoyalty Purchase Agreement • August 9th, 2021 • Agenus Inc • Biological products, (no disgnostic substances) • New York
This Amendment No. 1 to Royalty Purchase Agreement (this “Amendment”) is made and entered into as of June 22, 2021 by and among Antigenics LLC, a Delaware limited liability company (the “Seller”) and the entities set forth on Schedule 1 to the (as defined below) Agreement in the proportions set forth thereon (collectively, the “Buyer”). Capitalized terms used herein but not defined shall have the meanings ascribed to such terms in the Agreement (as defined below).
LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT DATED AS OF MAY 17, 2021 BY AND BETWEEN AGENUS INC. AND BRISTOL-MYERS SQUIBB COMPANYLicense, Development and Commercialization Agreement • August 9th, 2021 • Agenus Inc • Biological products, (no disgnostic substances) • New York
This License, Development and Commercialization Agreement (this “Agreement”), dated as of May 17, 2021 (the “Execution Date”), is made by and between Agenus Inc., a Delaware corporation with offices at 3 Forbes Road, Lexington, Massachusetts 02421 (“Agenus”), and Bristol-Myers Squibb Company, a Delaware corporation headquartered at 345 Park Avenue, New York, New York 10154 (“Licensee”). Agenus and Licensee are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
